I admit it: I buy stocks because it's fun.
Sure, it's nice to invest my daughter's tuition money in a diversified portfolio of individual stocks to make sure my community college budget will someday be able to pay for her Ivy League aspirations. And I can sleep well knowing that my index funds and 401(k) -- which hold the vast majority of my investments -- will continue to increase in value.
But with a small corner of my portfolio, I am able to chase the adrenaline rush that isn't readily available for those of us who have something against bungee jumping, mountain climbing, competitive eating, and all those other activities intentionally designed to put you several steps closer to death.
The money I put into stocks is invested in no small part for the sheer sense of drama. And there's no more dramatic, exciting, get-the-blood-pumping way to invest than in high-growth stocks. I'm buying shares in companies that could be floundering next month, or they could be the world-changing companies of tomorrow.
Consider the case of Capital One
Of course, I'm putting the odds in my favor by aligning my fates with some very smart folks. Scanning the scorecard of the Motley Fool Rule Breakers newsletter service, I can point to an overflowing handful of stocks that have moved more than 25% in a single day -- and the majority of those were on the plus side. The scorecard has seen a few drops -- that's the nature of high-growth investing -- but a lot more have made big upswings. Of the newsletter's 22 formal recommendations, nine are up more than 20% since they were picked. Eight are up 30%. Seven of 22 picks are up more than 40%. As an investor in some of those companies, I can tell you that's fun.
Few rides were more enjoyable than the skyrocket by the electronic exchange Archipelago
More recently, a company called Intuitive Surgical
Most of the picks on the scorecard have either made a huge leap or appear to be on the verge. There's a Chinese firm I think will be the next of the Rule Breakers picks to deliver one of those adrenaline-pumping days. And I've got my eye on two of the biotech firms on the scorecard -- with FDA approval looming for some of their major drugs, they're about ready to pop. I'm not going to tell you the companies -- have to save those for the subscribers -- but you can take a free, no-obligation look at the scorecard by taking a trial membership.
A world of high-growth opportunities
There are hundreds of companies in a watch list called Rule Breaker Universe that David, his team, and the Rule Breakers online community are analyzing for possible formal consideration. There's a small drug developer called BioMarin Pharmaceutical
Yet it's not just dot-com and pharmaceutical stocks that the Rule Breakers team looks for. Any company that grows itself with a competitive advantage by breaking the rules of business is fair game. That can be a drug manufacturer or a company like ZipRealty
Any of those innovations could go down in flames, or they could drive the 10-baggers that investors dream about.
How much fun is that?
To take advantage of Fool co-founder David Gardner's aforementioned 30-day free trial, simply click here. The moment you sign up, you'll have full access to everything we've ever published.
Roger Friedman is the managing editor of newsletters and the author of Nipple Confusion, Uncoordinated Pooping and Spittle: The Life of a Newborn's Father . He owns shares of Intuitive Surgical. Netflix is a Motley Fool Stock Advisor recommendation. The Motley Fool has a fulldisclosure policy.